CEL-SCI Corporation (CVM)

The immediate outlook is severely clouded by a relentless selling pressure triggered by repeated equity raises, which have repeatedly depressed the share price to test critical support levels. While the stock recently staged a technical bounce from lows near $1.00, the underlying mechanics remain dangerous: the company is diluting shareholders aggressively to fund a biotech pipeline while burning through cash at an alarming rate, evidenced by significant negative operating and free cash flows. The balance sheet is fragile, with debt significantly outweighing equity and current liabilities exceeding current assets, creating a precarious liquidity situation. Fundamentally, the business has undergone a catastrophic structural decline over the last decade, with the stock price collapsing by nearly 99% from its peak and suffering five consecutive years of negative annual returns. There is no dividend to provide income or a safety net. Although the statistical forecasting model suggests a potential short-term dip, its extremely low reliability makes it useless for decision-making in this context. The convergence of aggressive dilution, deepening losses, and a multi-year price implosion renders this a high-risk speculative vehicle rather than an investment opportunity.